NCT03292783 2021-07-07This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001ABL Bio, Inc.Phase 1 Completed45 enrolled